Global Human Milk Oligosaccharides (HMO) Market
Global Human Milk Oligosaccharides (HMO) Market Size Booming More Than 4X at Robust CAGR of 23% During 2023–2029
Published | 26 April 2023
Global Human Milk Oligosaccharides (HMO) market is gaining traction because of the growing awareness about the benefits of HMOs in infant nutrition, including supporting digestive health and technology advancements, such as microbial fermentation, enzymatic synthesis, and chemical synthesis, in HMO production.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global Human Milk Oligosaccharides (HMO) market size at USD 199 million in 2022. During the forecast period between 2023 and 2029, the global Human Milk Oligosaccharides (HMO) market size is projected to grow at a robust CAGR of 22.9% reaching a value of USD 842.78 million by 2029. The development of R&D efforts and the increasing usage of HMO as a component in infant formula are two major growth factors for the global market for HMO. One of the primary factors propelling the growth of the human milk oligosaccharides (HMO) market is the accessibility of cutting-edge technologies like enzymatic trans-glycosylation, which is used to artificially synthesis the HMOs.
Global Human Milk Oligosaccharides (HMO) Market – Overview
Human milk oligosaccharides (HMOs) are a group of complex carbohydrates and the third most prevalent solid substance in human milk after lipids and lactose. Mother's milk contains HMOs that are essential for the immune system and intestinal barrier development in a newborn. Some HMOs may also have an impact on how the infant's brain develops. Although there are more than 100 distinct kinds of HMOs, most moms' breast milk contains the most 2'-FL HMO (2'-fucosyllactose), which is the most common form.
Sample Request @ https://www.blueweaveconsulting.com/report/human-milk-oligosaccharides-market/report-sample
Global Human Milk Oligosaccharides (HMO) Market – By Application
Based on application, the global Human Milk Oligosaccharides (HMO) market is segmented into infant formula, functional food & beverages, food supplements, health ingredients, and others. The infant formula segment accounts for the highest market share. These HMO supplements shield newborns against infection. Additionally, it helps gut health maintenance, protects them from prebiotic effects, and boosts cognition. Therefore, most infant formula-making food companies add this component into their products, due to which its demand is gaining traction in the market.
Impact of COVID-19 on Global Human Milk Oligosaccharides (HMO) Market
The market for Human Milk Oligosaccharides (HMO) was significantly impacted by the COVID-19 pandemic. Due to panic buying for at-home consumption during the early stages of the pandemic, the demand for HMOs soared during the lockdown. Because HMOs operate as an immunity booster, their sales increased during the pandemic as a result. However, restrictions on production activities and a shortage of labor also created a huge demand and supply gap that impacted the market revenue negatively in the later period of the COVID-19 outbreak. But it is estimated that the market will overall gain new opportunities owing to the rising health consciousness among consumers.
Competitive Landscape
Major players operating in the global Human Milk Oligosaccharides (HMO) market include Abbott Laboratories, FrieslandCampina Domo, DuPont Nutrition & Health, Jennewein Biotechnologie GmbH, Glycom A/S, Nestle S.A., Inbiose NV, ZuChem Inc., InnoBio Ltd., Elicityl SA, TCI Chemicals (India) Pvt. Ltd., Medolac Laboratories, Glycosyn LLC, Glycosyn-Stanford JV LLC, and ProZomix Limited.
To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and the Global Human Milk Oligosaccharides (HMO) Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Human Milk Oligosaccharides (HMO) Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
About Us
BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive market research reports by analyzing qualitative and quantitative data to boost the performance of your business solutions. BlueWeave has built its reputation from scratch by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.
Contact Us:
BlueWeave Consulting & Research Pvt. Ltd
+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662
Get Help
Related Report
Publish Date: May 2024
The Human Milk Oligosaccharides (HMOs) market is experiencing rapid growth driven by increased awareness of their health benefits, especially in infant nutrition. Technological advancements in biotechnology are enhancing production scalability and cost-effectiveness. Rising demand for HMOs in infant formulas and functional foods, thanks to their resemblance to breast milk benefits, is a significant market driver, shaping the industry's expansion and innovation.
Relevant Press Releases
- Europe Emergency Food Market Size Expands to Reach USD 3.7 Billion by 2030
- India Food Safety Testing Market Booming to Touch Value of USD 637 Million by 2030
- Global Coconut Water Market Witnessing Steady Growth Despite the Pandemic: Projected to touch USD 13.1 Billion by 2027
- United States Food Safety Testing Market Booming at Significant CAGR to Surpass Value of USD 8.7 Billion by 2030
- Europe Protein-based Sports Drinks Market Grows at Healthy CAGR to Touch USD 650 Million by 2030